news

CUPERTINO, Calif., Aug. 6, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2012. Total revenues were $4.8 million for the three months ended June 30, 2012 as compared to $7.8 million for the three months ended June 30, 2011.  Net loss for the three months […]

CUPERTINO, Calif., Aug. 6, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed its pre-NDA communications  with the United States Food and Drug Administration (FDA) regarding POSIDUR™ (SABER®-Bupivacaine).  Through this process, DURECT has received guidance and thoughtful comments from the FDA covering various chemistry, manufacturing, non-clinical, clinical pharmacology, clinical, statistical and

CUPERTINO, Calif., July 26, 2012 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) second quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 6, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., May 3, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2012. Excluding the accelerated recognition of deferred revenue described below, DURECT‘s reported revenues would have been $5.8 million for the three months ended March 31, 2012 (as compared to $8.6 million for the same

New Patents Broaden and Extend Protection for REMOXY® and other ORADUR-based Opioids CUPERTINO, Calif., May 3, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the issuance of four patents by the United States Patent and Trademark Office (USPTO) covering DURECT‘s ORADUR technology.  These patents provide additional intellectual property protection for REMOXY (oxycodone) Extended-Release Capsules

CUPERTINO, Calif., April 25, 2012 /PRNewswire via COMTEX/ –In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 3, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., March 29, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today reported that Hospira, Inc. has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER®-Bupivacaine) in the U.S. and Canada.  POSIDUR is a post-operative pain relief depot that utilizes DURECT‘s patented SABER technology to deliver bupivacaine and is designed to

CUPERTINO, Calif., March 1, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2011. Total revenues were $8.9 million for the three months ended December 31, 2011, up from $8.5 million for the three months ended December 31, 2010.  Net loss for the three

CUPERTINO, Calif., Feb. 24, 2012 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) fourth quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, March 1, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., Feb. 23, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) James E. Brown, President and CEO, will present at the RBC Capital Markets‘ Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. Eastern Time.  The conference is being held